VYNE Therapeutics (VYNE)
(Delayed Data from NSDQ)
$0.30 USD
-0.01 (-1.87%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $0.32 +0.02 (5.19%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VYNE 0.30 -0.01(-1.87%)
Will VYNE be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for VYNE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VYNE
VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Lags Revenue Estimates
Metagenomi (MGX) Reports Q2 Loss, Tops Revenue Estimates
VYNE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aquestive Therapeutics (AQST) Reports Q2 Loss, Lags Revenue Estimates
Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Surpass Estimates
VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates
Other News for VYNE
VYNE forms 20 Day Moving Average Resistance on September 20
Hammer Candlestick appears for VYNE after 1.94% move
NR7 appears for VYNE after 0.62% move
VYNE forms 20 Day Moving Average Resistance on September 16
VYNE forms Bollinger Band Squeeze on September 15